Clinical Trial Update: A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine [Phase 3]

View source ↗

Summary

Phase 3 pediatric study evaluating adverse events and changes in disease activity for oral atogepant in children aged 6-17 with episodic migraine; currently rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Episodic Migraine

Drugs mentioned

• Qulipta (atogepant)

Snippet

Sponsor: AbbVie | Conditions: Episodic Migraine | Phase 3 | Status: RECRUITING